Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfon
| Current Price | ₹380.85 |
|---|---|
| Market Cap | ₹3,476 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 17.8 |
| Return on Equity | 13.36% |
| 52-Week Range | ₹318.60 – ₹574.95 |
| Beta (1Y) | 0.73 |
| Dividend Yield | 0.53% |
1. Pharmaceuticals-100%
Aarti Drugs Ltd. is trading at ₹380.85, with a market capitalisation of ₹3,476 Cr.
Aarti Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Aarti Drugs Ltd. has a P/E of 17.8 and a return on equity of 13.36%.